Yokohama, Japan – Johnson & Johnson MedTech, a leading global innovator in cardiac arrhythmia solutions, has announced the presentation of notable new clinical and real-world data pertaining to its VARIPULSE™ Platform at the joint annual meeting of the Asia Pacific Heart rhythm Society (APHRS) and the Japanese Heart Rhythm Society (JHRS) in Yokohama, Japan, November 12-15, 2025. The data focuses on pulsed field ablation (PFA) procedures for atrial fibrillation (AF), a common heart rhythm disorder.
VARIPULSE Platform Gains Momentum
The VARIPULSE™ Platform, which comprises the VARIPULSE™ Catheter, TRUPULSE™ Generator, and CARTO™ 3 Mapping System VARIPULSE™ Software, has already received regulatory approvals in the United States, europe, Asia Pacific, Canada, and Latin America. johnson & Johnson MedTech reported that over 25,000 procedures utilizing the platform have been successfully completed across multiple countries, including the U.S.,Europe,Canada,Japan,Hong Kong,mainland China,Korea,Taiwan,and Australia.
The company emphasized its commitment to advancing scientific understanding and collaborative efforts to improve patient outcomes through the presentation of this new evidence.A series of educational events, including symposia, demonstrations, and sessions, will also be hosted by Johnson & Johnson MedTech at the APHRS and JHRS conferences.
Key Research Highlights
Jing Li,Vice President,electrophysiology & Neurovascular,Asia Pacific MedTech,johnson & Johnson,stated that the presented evidence showcases the strength of their integrated CARTO™ 3 Mapping System and VARIPULSE™ Platform. Key data presentations include:
- QUEST BY: An oral presentation detailing the accomplished acute outcomes of persistent atrial fibrillation ablation using a temperature-controlled, high-power, short-duration radiofrequency catheter, based on initial real-world experience from the QUEST AF study.
- VARIPURE (SECURE): A poster presentation analyzing the workflow, efficiency, and vein-level results of a novel pulsed field ablation catheter with a variable loop circle design in AF procedures, drawing insights from the VARIPURE study.
- admIRE: An oral session examining the impact of patient age and the time between diagnosis and ablation on sex-based differences in 12-month outcomes post-catheter ablation for atrial fibrillation, along with a subanalysis of same-day discharge after pulsed field ablation.
- REAL BY: Several poster and oral presentations covering critical aspects of ablation efficacy, including right-sided first pass isolation, the importance of bilateral first pass isolation, the benefits of carina ablation, and a retrospective study on sex differences in left atrial scar burden and atrial fibrillation outcomes.
Johnson & Johnson MedTech intends to continue its collaboration with the medical community to expand the body of evidence supporting the VARIPULSE™ Platform and accelerate innovation in atrial fibrillation care.
Cardiovascular Innovation at Johnson & Johnson MedTech
Johnson & Johnson MedTech is focused on tackling significant health challenges, particularly in cardiovascular disease. Through a broad portfolio of advanced technologies-including mapping, navigation, miniaturized devices, and precise ablation systems-the company is addressing conditions like heart failure, coronary artery disease, stroke, and atrial fibrillation. They are a global leader in heart recovery, circulatory restoration, and heart rhythm treatment, with a growing presence in neurovascular care.
Did You No? Atrial fibrillation affects millions globally and significantly increases the risk of stroke. innovative treatments like pulsed field ablation are offering new hope for patients.
| platform Component | Function |
|---|---|
| VARIPULSE™ Catheter | Delivers pulsed electric fields to ablate heart tissue. |
| TRUPULSE™ Generator | Powers the VARIPULSE™ Catheter. |
| CARTO™ 3 Mapping System VARIPULSE™ Software | Creates detailed 3D maps of the heart to guide ablation procedures. |
pro Tip: Early detection and treatment of atrial fibrillation are crucial for preventing complications. Talk to your doctor if you experience symptoms like irregular heartbeat, shortness of breath, or fatigue.
Understanding Atrial Fibrillation: Atrial fibrillation is an irregular and often rapid heart rate that can increase the risk of stroke, heart failure and other heart-related complications. While it isn’t life-threatening in itself, it requires proper management. According to the centers for Disease Control and Prevention (CDC), approximately 2.7 to 6.1 million americans are affected by AFib.
Pulsed Field Ablation (PFA): PFA is a relatively new approach to treating atrial fibrillation. Unlike customary methods that use heat to create scars in the heart tissue, PFA utilizes electrical energy to selectively target and ablate problematic cells causing the irregular heartbeat. This newer technology aims to reduce the risk of collateral damage to surrounding healthy tissue.
Frequently Asked Questions About Atrial Fibrillation and VARIPULSE™
- What is atrial fibrillation? Atrial fibrillation is an irregular heartbeat that can lead to serious health complications.
- How does the VARIPULSE™ Platform treat atrial fibrillation? The VARIPULSE™ Platform utilizes pulsed field ablation to selectively target and eliminate the source of irregular heartbeats.
- What are the benefits of pulsed field ablation over traditional methods? PFA aims to minimize damage to surrounding healthy heart tissue.
- Is the VARIPULSE™ Platform widely available? the platform is approved for use in multiple countries, including the U.S., Europe, and Asia Pacific.
- What kind of data supports the effectiveness of VARIPULSE™? Data from over 25,000 procedures and ongoing clinical trials like QUEST BY, VARIPURE, and admIRE demonstrate promising results.
- What are the potential risks associated with atrial fibrillation treatment? Like all medical procedures, there are potential risks involved. It’s essential to discuss these with your doctor.
- Where can I find more details about Johnson & Johnson MedTech’s cardiovascular solutions? Visit biosensewebster.com for detailed information.
What are your thoughts on the advancements in atrial fibrillation treatment? Share your opinions in the comments below!
